Irbesartan Amarox (Irbesartan)

Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors on blood vessels, adrenal glands and renal cells. This inhibition prevents angiotensin‑II‑mediated vasoconstriction, aldosterone release and sympathetic activation, resulting in vasodilation, reduced sodium retention and lower blood pressure, while also decreasing intraglomerular pressure in the kidneys.

The dose of Irbesartan Amarox is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and other clinical factors. The prescriber determines the appropriate strength, frequency and any titration schedule needed for safe and effective therapy.

Safety data for irbesartan in pregnancy are limited, and the drug is generally avoided in the second and third trimesters because of potential fetal harm. Breastfeeding mothers should discuss risks with their healthcare provider, as the medication may pass into breast milk.

To request Irbesartan Amarox, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to irbesartan is the ACE‑inhibitor class. Both lower blood pressure by interfering with the renin‑angiotensin system, but ARBs like irbesartan are less likely to cause cough or angioedema. ACE inhibitors may be preferred when a stronger renin‑angiotensin blockade is required, while ARBs are often chosen for better tolerability.

Irbesartan Amarox should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Irbesartan Amarox is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, and the dosing schedule (once daily or as directed) is set by the prescriber based on the patient’s therapeutic needs.

Serious adverse events include angioedema, severe hyperkalemia, acute renal failure and hepatic injury. Patients should seek immediate medical attention if they develop swelling of the face or throat, unexplained muscle weakness, marked changes in urine output, or signs of liver dysfunction such as jaundice.

Irbesartan Amarox should be avoided in individuals with known hypersensitivity to irbesartan or other ARBs, in patients with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for patients with significant renal impairment or elevated serum potassium.